Replies to post #188162 on Biotech Values

[ciotera]

Re: ABBV, PCYC

Valuation aside, this is actually a good fit for Abbvie.
Gives it a head start in hematology (no need to build a sales force from scratch) and removes a key competitor in the US (where ABT-199 would be more disadvantaged vs. Imbruvica). Not to mention the obvious benefit of being able to combine different novel MOAs (they now have BTK, PI3K and BCL2 inhibitors in their portfolio) to create chemo-free regimens and mitigate TLS risks (e.g., treat with Imbruvica for 2 weeks then add ABT-199 to get to MRD).